

## PRESS RELEASE



PHILIP MORRIS INTERNATIONAL

Investor Relations:

Media:

New York: +1 (917) 663 2233

Lausanne: +41 (0)58 242 4500

Lausanne: +41 (0)58 242 4666

### **PHILIP MORRIS INTERNATIONAL INC. PRESENTS AT GOLDMAN SACHS GLOBAL STAPLES FORUM**

NEW YORK, May 12, 2015 – Philip Morris International Inc.'s (NYSE / Euronext Paris: PM) Chief Executive Officer, André Calantzopoulos, will address investors today at the Goldman Sachs Global Staples Forum in New York. He will be joined during the question and answer session by Chief Financial Officer Jacek Olczak.

The presentation and Q&A session are being webcast live, in a listen-only mode, beginning at approximately 9:30 a.m. ET, at [www.pmi.com/webcasts](http://www.pmi.com/webcasts).

An archived copy of the webcast will be available at [www.pmi.com/webcasts](http://www.pmi.com/webcasts) until 5:00 p.m. ET on Wednesday, June 10, 2015. Remarks and slides will also be available at [www.pmi.com/presentations](http://www.pmi.com/presentations).

###

#### **Philip Morris International Inc.**

Philip Morris International Inc. (PMI) is the leading international tobacco company, with six of the world's top 15 international brands, including *Marlboro*, the number one cigarette brand worldwide. PMI's products are sold in more than 180 markets. In 2014, the company held an estimated 15.6% share of the total international cigarette market outside of the U.S., or 28.6% excluding the People's Republic of China and the U.S. For more information, see [www.pmi.com](http://www.pmi.com).

Reduced-Risk Products ("RRPs") is the term the company uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking combustible cigarettes. PMI's RRP's are in various stages of development and commercialization, and we are conducting extensive and rigorous scientific studies to determine whether we can support claims for such products of reduced exposure to harmful and potentially harmful constituents in smoke, and ultimately claims of reduced disease risk, when compared to smoking combustible cigarettes. Before making any such claims, we will need to rigorously evaluate the full set of data from the relevant scientific studies to determine whether they substantiate reduced exposure or risk. Any such claims may also be subject to government review and approval, as is the case in the U.S. today.